Chimeric Antigen Receptor T Cell Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chimeric Antigen Receptor T Cell stocks.

Chimeric Antigen Receptor T Cell Stocks Recent News

Date Stock Title
May 13 SNTI Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13 NTLA Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 12 NTLA Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 11 NKTX Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10 NTLA Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript
May 10 NKTX Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis
May 10 NTLA Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances
May 10 NTLA Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
May 10 SNTI Senti Biosciences GAAP EPS of -$0.26
May 10 NTLA Intellia Therapeutics First Quarter 2024 Earnings: Beats Expectations
May 10 NTLA Q1 2024 Intellia Therapeutics Inc Earnings Call
May 9 NKTX Nkarta GAAP EPS of -$0.58 misses by $0.02
May 9 SNTI Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 9 NKTX Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
May 9 NTLA Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript
May 9 PSTX Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
May 9 NTLA Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
May 9 CARM Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
May 9 JANX We're Not Very Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Rate
May 9 CARM Carisma Therapeutics GAAP EPS of -$0.46 misses by $0.03, revenue of $3.39M misses by $1.01M
Chimeric Antigen Receptor T Cell

Chimeric Antigen Receptor T Cell (CAR-T) is a type of immunotherapy that uses a patient’s own T cells to fight cancer. The T cells are genetically modified to express a special receptor, called a chimeric antigen receptor (CAR), which is designed to recognize and bind to a specific protein found on the surface of cancer cells. Once the CAR-T cells bind to the cancer cells, they can kill them. CAR-T therapy has been used to treat certain types of blood cancers, such as leukemia and lymphoma, and is being studied for other types of cancer.

Browse All Tags